Search

Your search keyword '"Weynand B"' showing total 464 results
Start Over Author "Weynand B"
464 results on '"Weynand B"'

1. Characterization of Small Airway Obstruction Diversity in COPD

Author

Geudens, V., primary, De Fays, C., additional, Willems, L., additional, Vermaut, A., additional, Aerts, G., additional, Kerckhof, P., additional, Goos, T., additional, Kaes, J., additional, Hooft, C., additional, Jin, X., additional, Beeckmans, H., additional, Khaled Mohamed Elm Mohamady, Y., additional, Aversa, L., additional, Vermant, M., additional, Gyselinck, I., additional, Verhaegen, J., additional, Van Slambrouck, J., additional, Aelbrecht, C., additional, Higham, A., additional, Cortesi, E., additional, Vanstapel, A., additional, McDonough, J.E., additional, Carlon, M.S., additional, Quarck, R., additional, Boone, M., additional, Dupont, L., additional, Weynand, B., additional, Pilette, C., additional, Van Raemdonck, D.E., additional, Ceulemans, L.J., additional, Hogg, J.C., additional, Hackett, T.-L., additional, Vos, R., additional, Wuyts, W.A., additional, Janssens, W., additional, Vanaudenaerde, B., additional, and Gayan-Ramirez, G., additional

Published
2024
Full Text
View/download PDF

2. Expression of Exposed CLDN1 Is Linked to Early Pathological Lesions in Idiopathic Pulmonary Fibrosis

Author

Cortesi, E.E., primary, Anquetil, V., additional, Mcdonough, J.E., additional, Weynand, B., additional, Vanstapel, A., additional, Aelbrecht, C., additional, Aversa, L., additional, Aerts, G., additional, Geudens, V., additional, Xin, J., additional, Vermant, M., additional, Goos, T., additional, Gogaert, S., additional, Mohamady, Y.K.M.E., additional, Polini, E., additional, Toso, A., additional, El Saghire, H., additional, Meyer, M., additional, Baumert, T., additional, Toovey, S., additional, Manenti, L., additional, Iacone, R., additional, Christ, F., additional, Vanaudenaerde, B.M., additional, Teixeira, G., additional, De Sadeleer, L.J., additional, Wuyts, W.A., additional, and Carlon, M.S., additional

Published
2024
Full Text
View/download PDF

3. Micro-CT Based Approach to Quantitatively Evaluate Vascular Changes in Pulmonary Arterial Hypertension

Author

Aerts, G., primary, Willems, L., additional, Anthonissen, R., additional, De Jonghe, B., additional, Michiels, J., additional, Celen, R., additional, Verhaegen, J., additional, Vermaut, A., additional, Geudens, V., additional, Hooft, C., additional, Kerckhof, P., additional, Beeckmans, H., additional, Kaes, J., additional, Mohamady, Y., additional, Hardy, L., additional, Van Slambrouck, J., additional, Tielemans, B., additional, Weynand, B., additional, Ceulemans, L., additional, Vos, R., additional, Gayan-Ramirez, G., additional, Belge, C., additional, Verbelen, T., additional, Greetje, V., additional, Delcroix, M., additional, Quarck, R., additional, Vanaudenaerde, B., additional, and Godinas, L., additional

Published
2024
Full Text
View/download PDF

4. PL03.07 Invasion or No Invasion, That’s the Question. A Large Reproducibility Study in Pulmonary Adenocarcinoma, Supporting a Modified Classification

Author

Thunnissen, E., primary, Blaauwgeers, H., additional, Filipello, F., additional, Lissenberg-Witte, B., additional, Minami, Y., additional, Noguchi, M., additional, Le Quense, J., additional, Papotti, M.G., additional, Flieder, D., additional, Pelosi, G., additional, Sansano, I., additional, Berezowska, S., additional, Ryška, A., additional, Brcic, L., additional, Motoi, N., additional, Nakatani, Y., additional, Kuempers, C., additional, Hofman, P., additional, Hofman, V., additional, Grotnes Dale, V., additional, Rossi, G., additional, Ambrosi, F., additional, Matsubara, D., additional, Ishikawa, Y., additional, Weynand, B., additional, Calabrese, F., additional, Pezzuto, F., additional, Kern, I., additional, Nicholson, S., additional, Mutka, A.-L., additional, Dacic, S., additional, Beasley, M.B., additional, Arrigoni, G., additional, Timens, W., additional, Ooft, M., additional, Brinkhuis, M., additional, Bulkmans, N., additional, Britstra, R., additional, Vreuls, W., additional, Jones, K., additional, von der Thüsen, J., additional, Hager, H., additional, Perner, S., additional, Moore, D., additional, Leonte, D.G., additional, Al-Janabi, S., additional, Schønau, A., additional, Stenzinger, A., additional, and Kazdal, D., additional

Published
2023
Full Text
View/download PDF

5. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity

Author

Vanderbeke, L., Van Mol, P., Van Herck, Y., De Smet, F., Humblet-Baron, S., Martinod, K., Antoranz, A., Arijs, I., Boeckx, B., Bosisio, F. M., Casaer, M., Dauwe, D., De Wever, W., Dooms, C., Dreesen, E., Emmaneel, A., Filtjens, J., Gouwy, M., Gunst, J., Hermans, G., Jansen, S., Lagrou, K., Liston, A., Lorent, N., Meersseman, P., Mercier, T., Neyts, J., Odent, J., Panovska, D., Penttila, P. A., Pollet, E., Proost, P., Qian, J., Quintelier, K., Raes, J., Rex, S., Saeys, Y., Sprooten, J., Tejpar, S., Testelmans, D., Thevissen, K., Van Buyten, T., Vandenhaute, J., Van Gassen, S., Velásquez Pereira, L. C., Vos, R., Weynand, B., Wilmer, A., Yserbyt, J., Garg, A. D., Matthys, P., Wouters, C., Lambrechts, D., Wauters, E., and Wauters, J.

Published
2021
Full Text
View/download PDF

6. Correspondence Between Audible Crackles and Lung Function Test Results

Author

Gogaert, S., primary, Goos, T., additional, Vermant, M., additional, Carlon, M.S., additional, De Crem, N., additional, De Sadeleer, L., additional, De Langhe, E., additional, Dubbeldam, A., additional, Vanaudenaerde, B., additional, Verschakelen, J., additional, Weynand, B., additional, Yserbyt, J., additional, Bertrand, A., additional, De Vos, M., additional, and Wuyts, W.A., additional

Published
2023
Full Text
View/download PDF

7. Current Definitions of Progressive Pulmonary Fibrosis Might Be Inaccurate: Data From a Cohort of Patients With Rheumatoid Arthritis Associated Interstitial Lung Disease

Author

Vermant, M., primary, Goos, T., additional, Gogaert, S., additional, Carlon, M.S., additional, De Crem, N., additional, De Sadeleer, L., additional, De Langhe, E., additional, Dubbeldam, A., additional, Vanaudenaerde, B., additional, Verbeken, E., additional, Verschakelen, J., additional, Weynand, B., additional, Yserbyt, J., additional, Westhovens, R., additional, Verschueren, P., additional, and Wuyts, W.A., additional

Published
2023
Full Text
View/download PDF

8. Intrafamilial Correlation and Variability in the Clinical Evolution of Pulmonary Fibrosis

Author

Goos, T., primary, Dubbeldam, A., additional, Vermant, M., additional, Gogaert, S., additional, De Sadeleer, L.J., additional, De Crem, N., additional, De Langhe, E., additional, Yserbyt, J., additional, Weynand, B., additional, Carlon, M.S., additional, Verschakelen, J., additional, Vermeer, S., additional, Verleden, S.E., additional, and Wuyts, W.A., additional

Published
2023
Full Text
View/download PDF

9. Expression of phosphorylated ribosomal protein S6 in mesothelioma patients-correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project (Oct, 10.1038/s41379-022-01170-z, 2022)

Author

Ruschoff, J.H., Haberecker, M., Tsourti, Z., Nackaerts, K., Perrot, M. de, Brcic, L., Nadal, E., Tsimpoukis, S., Gray, S.G., Ampollini, L., Aerts, J.G., Felley-Bosco, E., Kirschner, M.B., Monkhorst, K., Weynand, B., Bavaghar-Zaeimi, F., Samarzija, M., Llatjos, R., Finn, S.P., Silini, E., Thusen, J. von der, Marti, N., Vervita, K., Kammler, R., Peters, S., Stahel, R.A., Baas, P., Opitz, I., and Consortium, E.M.

Published
2022

10. Family history of ILD predicts pulmonary function decline in IPF patients

Author

Goos, T, primary, Vermant, M, additional, De Sadeleer, L J, additional, Verstraete, K, additional, De Crem, N, additional, De Langhe, E, additional, Dubbeldam, A, additional, Verbeken, E K, additional, Verschakelen, J, additional, Weynand, B, additional, Yserbyt, J, additional, Vermeer, S, additional, Verleden, S E, additional, and Wuyts, W A, additional

Published
2022
Full Text
View/download PDF

13. Evolution of diffusion capacity in interstitial lung disease associated with rheumatoid arthritis

Author

Vermant, M, primary, Goos, T, additional, Bode, H, additional, De Sadeleer, L J, additional, Verstraete, K, additional, De Crem, N, additional, De Langhe, E, additional, Dubbeldam, A, additional, Verbeken, E, additional, Verschakelen, J, additional, Weynand, B, additional, Yserbyt, J, additional, Westhovens, R, additional, Verschueren, P, additional, and Wuyts, W A, additional

Published
2022
Full Text
View/download PDF

14. (212) - Micro-CT Based Approach to Quantitatively Evaluate Vascular Changes in Pulmonary Arterial Hypertension

Author

Willems, L., Anthonissen, R., De Jonghe, B., Michiels, J., Celen, R., Verhaegen, J., Vermaut, A., Geudens, V., Hooft, C., Kerckhof, P., Beeckmans, H., Kaes, J., Mohamady, Y., Hardy, L., Van Slambrouck, J., Tielemans, B., Weynand, B., Ceulemans, L., Vos, R., Gayan-Ramirez, G., Belge, C., Verbelen, T., Greetje, V., Delcroix, M., Quarck, R., Vanaudenaerde, B., and Godinas, L.

Published
2024
Full Text
View/download PDF

15. The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern

Author

Abdelnabi, R, Foo, CS, Jochmans, D, Vangeel, L, De Jonghe, S, Augustijns, P, Mols, R, Weynand, B, Wattanakul, T, Hoglund, RM, Tarning, J, Mowbray, CE, Sjö, P, Escudié, F, Scandale, I, Chatelain, E, and Neyts, J

Subjects
Multidisciplinary, Lactams, Mesocricetus, Proline, Viral Protease Inhibitors, SARS-CoV-2, fungi, General Physics and Astronomy, Administration, Oral, COVID-19, General Chemistry, Respiratory Mucosa, Virus Replication, General Biochemistry, Genetics and Molecular Biology, COVID-19 Drug Treatment, Disease Models, Animal, A549 Cells, Leucine, Cricetinae, Chlorocebus aethiops, Nitriles, Animals, Humans, Vero Cells, Coronavirus 3C Proteases
Abstract

There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF-332 exerts equipotent in vitro activity against the four SARS-CoV-2 variants of concerns (VoC) and that it can completely arrest replication of the alpha variant in primary human airway epithelial cells grown at the air-liquid interface. Treatment of Syrian Golden hamsters with PF-332 (250 mg/kg, twice daily) completely protected the animals against intranasal infection with the beta (B.1.351) and delta (B.1.617.2) SARS-CoV-2 variants. Moreover, treatment of SARS-CoV-2 (B.1.617.2) infected animals with PF-332 completely prevented transmission to untreated co-housed sentinels. ispartof: NATURE COMMUNICATIONS vol:13 issue:1 ispartof: location:England status: published

Published
2021

21. Sertraline-induced chronic eosinophilic pneumonia

Author

Brancaleone, P, Descamps, O, Piquet, M, Detry, G, Mignon, M, and Weynand, B

Subjects
Pneumopathie médicamenteuse, Serotonin reuptake inhibitors, Depression, Pneumonie à éosinophiles, Sertraline, Dépression, Inhibiteurs de la recapture de la sérotonine, Pulmonary eosinophilia, Drug-induced lung disease
Abstract

INTRODUCTION: Sertraline is a selective serotonin reuptake inhibitor which is often used as first-line treatment for depression. Several patterns of interstitial lung disease attributable to sertraline have been reported in the literature. CASE REPORT: A 69-year-old patient, who had been taking sertraline to treat severe depression for 10 months, presented with a deterioration in his general condition and respiratory symptoms found to be associated with bilateral pneumonitis. An exhaustive assessment did not reveal any infectious or autoimmune aetiology. Transthoracic lung biopsy revealed a pattern of eosinophilic lung disease. Sertraline-induced lung toxicity was then suspected and this treatment was therefore stopped. The patient's symptoms resolved and the chest imaging normalized. CONCLUSIONS: Our observation suggests that sertraline was the cause of chronic eosinophilic pneumonia characterized by an insidious clinical presentation several months after starting the medication. Given its widespread prescription, we encourage any clinician facing this disease to pay attention to possible drug-induced origins of lung disease. ispartof: REVUE DES MALADIES RESPIRATOIRES vol:38 issue:2 pages:210-214 ispartof: location:France status: published

Published
2021

24. An Unusual Course of Donor-Transmitted Angiosarcoma after Lung Transplantation

Author

Bos, S., primary, Daniëls, L., additional, Michaux, L., additional, Bempt, I. Vanden, additional, Vermeer, S., additional, Woei-A-Jin, S., additional, Schöffski, P., additional, Weynand, B., additional, Sciot, R., additional, Declercq, S., additional, Van Raemdonck, D.E., additional, Ceulemans, L.J., additional, Dupont, L.J., additional, Verleden, G.M., additional, and Vos, R., additional

Published
2021
Full Text
View/download PDF

25. Phenotypical Characterization of Airway Morphology in Post-Infectious vs Post-Lung Transplantation Bronchiolitis Obliterans

Author

Vanstapel, A., primary, Weynand, B., additional, De Zutter, A., additional, Dubbeldam, A., additional, De Sadeleer, L., additional, Kaes, J., additional, Verbeken, E., additional, Ceulemans, L., additional, Geudens, V., additional, Goos, T., additional, Gyselinck, I., additional, Van Raemdonck, D., additional, Neyrinck, A., additional, Dupont, L., additional, Boon, M., additional, Boone, M., additional, Vanaudenaerde, B., additional, Vos, R., additional, Verleden, G., additional, and Verleden, S., additional

Published
2021
Full Text
View/download PDF

26. Connective Tissue Growth Factor in Chronic Lung Allograft Dysfunction: An Explorative Study

Author

Vanstapel, A., primary, Goldschmeding, R., additional, Broekhuizen, R., additional, Nguyen, T., additional, Sacreas, A., additional, Kaes, J., additional, Heigl, T., additional, Verleden, S., additional, Verleden, G., additional, Weynand, B., additional, Verbeken, E., additional, Ceulemans, L., additional, Van Raemdonck, D., additional, Neyrinck, A., additional, Schoemans, H., additional, Vanaudenaerde, B., additional, and Vos, R., additional

Published
2021
Full Text
View/download PDF

28. Résumés

Author

Jakobs, R., Debonne, J. -M., Rey, P., Klotz, F., Bresson-Hadni, Solange, Bartholomot, Brigitte, Bastid, C., Palazzo, L., Delvaux, M., Sempoux, Christine, Galant, C., Deprez, P., Borbath, I., Gigot, J. -F., Weynand, B., Sautereau, D., May, Andrea, and Schumacher, Brigitte

Published
2004
Full Text
View/download PDF

29. Successful treatment of Acanthamoeba rhinosinusitis in a patient with AIDS

Author

Nachega, J.B., Rombaux, P., Weynand, B., Thomas, G., and Zech, F.

Subjects
HIV patients -- Health aspects, Sinusitis -- Drug therapy, AIDS (Disease) -- Drug therapy, Health
Abstract

Acanthamoeba infection is a rare, difficult-to-treat, and often fatal, opportunistic parasitic infection in immunocompromised hosts, such as patients infected with HIV. We describe an aggressive nasal and sinus infection by Acanthamoeba spp. in a person with AIDS. The resolution of this Acanthamoeba infection was secondary to a multidisciplinary treatment approach involving a combination of surgery as well as high-dose amphotericin B plus 5-fluorocytosine. In the era of the HIV/AIDS pandemic, the present report underscores the need for early identification and prompt aggressive treatment to ensure successful management of this rare but potentially fatal opportunistic infection.

Published
2005

32. Histopathologic and Radiologic Assessment of Unused Donor Lungs: When to Decline or Not?

Author

Vanstapel, A., primary, Dubbeldam, A., additional, Weynand, B., additional, Verbeken, E.K., additional, Vos, R., additional, Neyrinck, A.P., additional, Ceulemans, L.J., additional, Frick, A.E., additional, Van Raemdonck, D.E., additional, Verschakelen, J., additional, Vanaudenaerde, B.M., additional, Verleden, G.M., additional, and Verleden, S.E., additional

Published
2020
Full Text
View/download PDF

33. Monocyte-Driven Atypical Cytokine Storm and Aberrant Neutrophil Activation as Key Mediators of COVID19 Disease Severity

Author

Vanderbeke, Lore, primary, Van Mol, Pierre, additional, Van Herck, Y, additional, De Smet, F, additional, Humblet-Baron, S, additional, Martinod, K, additional, Antoranz, A, additional, Arijs, I, additional, Boeckx, B, additional, Bosisio, FM, additional, Casaer, M, additional, Dauwe, D, additional, De Wever, W, additional, Dooms, Christophe, additional, Dreesen, E, additional, Emmaneel, A, additional, Filtjens, J, additional, Gouwy, M, additional, Gunst, J, additional, Hermans, G, additional, Jansen, S, additional, Lagrou, K, additional, Liston, A, additional, Lorent, N, additional, Meersseman, P, additional, Mercier, T, additional, Neyts, J, additional, Odent, J, additional, Panovska, Dena, additional, Penttila, PA, additional, Pollet, E, additional, Proost, P, additional, Qian, J, additional, Quintelier, K, additional, Raes, J, additional, Rex, S, additional, Saeys, Yvan, additional, Sprooten, J, additional, Tejpar, S, additional, Testelmans, D, additional, Thevissen, K, additional, Van Buyten, T, additional, Vandenhaute, J, additional, Van Gassen, S, additional, Velásquez Pereira, LC, additional, Vos, R, additional, Weynand, B, additional, Wilmer, A, additional, Yserbyt, J, additional, Garg, Abhishek, additional, Matthys, P, additional, Wouters, C, additional, Lambrechts, D, additional, Wauters, Els, additional, and Wauters, J, additional

Published
2020
Full Text
View/download PDF

34. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

Author

Thunnissen, E., primary, Lissenberg-Witte, B.I., additional, van den Heuvel, M.M., additional, Monkhorst, K., additional, Skov, B.G., additional, Sørensen, J.B., additional, Mellemgaard, A., additional, Dingemans, A.M.C., additional, Speel, E.J.M., additional, de Langen, A.J., additional, Hashemi, S.M.S., additional, Bahce, I., additional, van der Drift, M.A., additional, Looijen-Salamon, M.G., additional, Gosney, J., additional, Postmus, P.E., additional, Samii, S.M.S., additional, Duplaquet, F, additional, Weynand, B., additional, Durando, X., additional, Penault-Llorca, F., additional, Finn, S., additional, Grady, A.O, additional, Oz, B., additional, Akyurek, N., additional, Buettner, R., additional, Wolf, J., additional, Bubendorf, L., additional, Duin, S., additional, Marondel, I., additional, Heukamp, L.C., additional, Timens, W., additional, Schuuring, E.M.D., additional, Pauwels, P., additional, and Smit, E.F., additional

Published
2019
Full Text
View/download PDF

38. Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative

Author

Smit, E., Akyurek, N., Oz, B., Finn, S., Buettner, R., Pauwels, P., Schuuring, E., Timens, W., Marondel, L., Duin, S., Hiemstra, A., Bubendorf, L., Wolf, J., Penault-Llorca, F., Postmus, P. E., Durando, X., Gosney, J., Weynand, B., Duplaquet, F., Samii, S., Thunnissen, E., Lissenberg-Witte, B., Van den Heuvel, M., Monkhorst, K., Skov, B., Sorensen, J., Mellemgaard, A., Dingemans, A., Speel, E., Salomon, M. Looijen, De langen, J., Hashemi, S., Bahce, I., Van Der Drift, M., Groningen Research Institute for Asthma and COPD (GRIAC), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Targeted Gynaecologic Oncology (TARGON)

Subjects
crizotinib, ALK validation, hemic and lymphatic diseases, survival
Abstract

Background Metastasized NSCLC with an ALK fusion are sensitive to a range of tyrosine kinase inhibitors. ALK-positive NSCLC has been identified in the pivotal phase III trial with fluorescence in situ hybridization (ALK FISH+). These tumors are also expressing the fusion product (ALK immunohistochemistry (IHC)+). However, discrepant cases occur, including ALK IHC+ FISH-. The aim of this study was to collect ALK IHC+ cases and compare within this group response to crizotinib treatment of ALK FISH+ cases with ALK FISH- cases. Method A prospective multicenter investigator initiated research study was started in Europe. Stage IV ALK IHC+ NSCLC cases treated with crizotinib were collected centrally. Slides were validated centrally for ALK IHC (with 5A4 ETOP and D5F3 Ventana protocol) and ALK FISH (Vysis probes). Result The study started April 1, 2014 and closed in November 2017. Fifteen centers participated. Registration of 3523 ALK IHC tests revealed prevalence of 2.6% ALK IHC+ cases. Local ALK FISH analysis resulted in 46 concordant (ALK IHC+/FISH+) and 18 discordant (ALK IHC+/FISH-) cases. Central validation revealed 37 concordant and 6 discordant cases, 5 of which had follow-up. Validation was hampered by limited amount of tissue in biopsy samples. The time to treatment failure did not differ for concordant nor discordant cases, and neither for local nor validated ALK testing (HR=0.78; 95% CI= 0.27-2.3; p=0.64) and (HR=2.2; 95% CI= 0.72-6.5; p=0.16), respectively). However, overall survival was significantly better for concordant cases than discordant cases after central validation (HR=4.5; 95% CI= 1.2-15.9; p=0.010), but not according to local testing (HR=1.7; 95% CI= 0.45-6.2; p=0.44). Conclusion ALK IHC+ FISH- NSCLC cases are an infrequent finding. We recommend such cases to be validated carefully because our data indicate that ALK IHC+ FISH- cases have a worse survival when treated by crizotinib compared to ALK IHC+ FISH+ cases. This study was funded by an independent research grant by Pfizer.

Published
2018

41. Cytopathology in Belgium

Author

Drijkoningen, M., Bogers, J-P., Bourgain, C., Cuvelier, C., Delvenne, P., Gompel, C., Saerens, L., Thienpont, L., Van Damme, B., Van Eycken, L., Verhest, A., and Weynand, B.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results